Peipei Ye

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: October 26, 2024

Pancreatic atrophy and pancreatic exocrine insufficiency after allogeneic hematopoietic stem cell transplantation: a case report and literature review

Pancreatic atrophy and pancreatic exocrine insufficiency after allogeneic hematopoietic stem cell transplantation: a case report and literature review

Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series.

Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series.

Research progress of dengue virus T cell epitope mediated cellular immunity in avoiding ADE.

Research progress of dengue virus T cell epitope mediated cellular immunity in avoiding ADE.

A case series: cytomegalovirus retinitis following autologous hematopoietic cell transplantation: a call for early detection and aggressive management.

A case series: cytomegalovirus retinitis following autologous hematopoietic cell transplantation: a call for early detection and aggressive management.

A prospective, multicenter study on stem cell mobilization using the EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma.

A prospective, multicenter study on stem cell mobilization using the EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma.

Analysis of remobilization efficiency of etoposide combined with cytarabine and pegfilgrastim, with or without plerixafor, for multiple myeloma recurrence following autologous hematopoietic stem cell transplantation.

Analysis of remobilization efficiency of etoposide combined with cytarabine and pegfilgrastim, with or without plerixafor, for multiple myeloma recurrence following autologous hematopoietic stem cell transplantation.

TIM-3 blockade reverses oncolytic vaccinia virus-induced DCs inactivation and T cells exhaustion to improve antitumor immunity and therapeutic efficacy.

TIM-3 blockade reverses oncolytic vaccinia virus-induced DCs inactivation and T cells exhaustion to improve antitumor immunity and therapeutic efficacy.

Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low-Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag.

Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low-Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag.

Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.

Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.

Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis.

Hematopoietic progenitor kinase 1 inhibitor BGB-15025 induces apoptosis in acute myeloid leukemia cells through the cell cycle pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway signaling axis.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.

Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma.